Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry

Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry

Abstract Biologic and targeted synthetic disease-modifying antirheumatic drugs (ts/bDMARDs) play a pivotal role in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Persistence of therapy provides an index of a drug’s overall effectiveness. The o...

Full description

Bibliographic Details
Main Authors:	A. Prior-Español, C. Sánchez-Piedra, J. Campos, F. J. Manero, C. Pérez-García, C. Bohórquez, N. Busquets-Pérez, J. M. Blanco-Madrigal, C. Díaz-Torne, F. Sánchez-Alonso, L. Mateo, S. Holgado-Pérez
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-05-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-021-90442-w

Similar Items

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
by: Gerd Burmester, et al.
Published: (2020-05-01)

Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years
by: Carlos Sánchez-Piedra, et al.
Published: (2021-07-01)

Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register
by: Paloma Vela, et al.
Published: (2020-06-01)

bDMARDs retention rate in the biosimilar era: A real-life monocentric study
by: Andrea Becciolini, et al.
Published: (2021-04-01)

Data from the Romanian Registry of Rheumatic Diseases (RRBR) for patients with axial spondyloarthritis treated with biologic disease-modifying anti-rheumatic drugs (bDMARDs) during 2019
by: Ruxandra Ionescu, et al.
Published: (2020-03-01)

The pharmacological and clinical aspects behind dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs): rationale and systematic narrative review of clinical evidence
by: Gerlienke E. Geurts-Voerman, et al.
Published: (2020-07-01)

Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis
by: Seulkee Lee, et al.
Published: (2021-10-01)

In Patients with Early Peripheral Psoriatic Arthritis Baseline C-Reactive Protein, Pain and Ultrasound-Detected Synovitis Predict Subsequent Treatment with ts/bDMARDs. A Retrospective Analysis
by: Garifallia Sakellariou, et al.
Published: (2021-06-01)

Survival of bDMARDs in bionaive patients with rheumatoid arthritis: data from a retrospective 12-month follow-up
by: E. S. Aronova, et al.
Published: (2020-06-01)

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria
by: Konstantin Tachkov, et al.
Published: (2021-01-01)

Improvement of HbA1c in Patients with Type 2 Diabetes Mellitus and Rheumatoid Arthritis Treated with bDMARDs
by: Lurati A, et al.
Published: (2021-04-01)

Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis
by: D. Vinson, et al.
Published: (2020-04-01)

Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER
by: Juan José Bethencourt Baute, et al.
Published: (2018-10-01)

Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis
by: Van De Laar CJ, et al.
Published: (2020-04-01)

To Investigate the Effect of Disease Modifying Anti-Rheumatic Drugs (DMARDs) on the Foam Cell Formation
by: JIAN, HAN-SIOU, et al.
Published: (2014)

Evolución clínica de pacientes con artritis reumatoide con actividad alta y moderada tratados con bDMARDS, medida con DAS28. Fundación Investigación Médica del Atlántico
by: Dayana Morales, et al.
Published: (2015-12-01)

DMARDs–Gut Microbiota Feedback: Implications in the Response to Therapy
by: Oscar Zaragoza-García, et al.
Published: (2020-10-01)

Saudi cultural adaptation of the “compliance questionnaire of Rheumatology” for Rheumatoid arthritis patients on disease modifying anti-rheumatic drugs (DMARDs)
by: Roaa Aljohani, et al.
Published: (2021-05-01)

‘Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?’
by: Michael D George, et al.
Published: (2020-08-01)

Methrotexate Treatment Inmunomodulates Abnormal Cytokine Expression by T CD4 Lymphocytes Present in DMARD-Naïve Rheumatoid Arthritis Patients
by: Jorge Monserrat Sanz, et al.
Published: (2020-09-01)

Safety of Biologic-DMARDs in Rheumatic Musculoskeletal Disorders: A Population-Based Study over the First Two Waves of COVID-19 Outbreak
by: Colatutto, D., et al.
Published: (2022)

The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice
by: Lynden Roberts, et al.
Published: (2017-01-01)

Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs
by: William F. C. Rigby, et al.
Published: (2017-01-01)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
by: Mysler E, et al.
Published: (2021-06-01)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
by: Thomas R Riley
Published: (2021-04-01)

A 4-year non-randomized comparative phase-IV study of early rheumatoid arthritis: integrative anthroposophic medicine for patients with preference against DMARDs versus conventional therapy including DMARDs for patients without preference
by: Hamre HJ, et al.
Published: (2018-03-01)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies
by: Ferrufino CP, et al.
Published: (2018-11-01)

Clinical evaluation of DMARDs and NSAIDs in cases of Rheumatoid arthritis in Chhattisgarh
by: Basant Kumar Maheshwari
Published: (2018-01-01)

Effect of immunomodulating treatment (usage of DMARDs) in rheumatoid arthritis on depression
by: Magdalena Kozyra, et al.
Published: (2020-08-01)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]
by: Ferrufino CP, et al.
Published: (2019-01-01)

Doctors’ preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment
by: T. Martijn Kuijper, et al.
Published: (2017-04-01)

DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS
by: Maria Sergeevna Voronina, et al.
Published: (2012-10-01)

Rheumatoid arthritis seems to have DMARD treatment decision influenced by fibromyalgia
by: Rafael Mendonça da Silva Chakr, et al.

Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone
by: Carl K Edwards, et al.
Published: (2012-12-01)

T.S. Eliot : post-symbolist
by: Romer, S. C. M.
Published: (1985)

Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors
by: Gerasimos Evangelatos, et al.
Published: (2020-06-01)

Varicella immunity and vaccine response in children with juvenile idiopathic arthritis treated with DMARD
by: Nordal EB, et al.
Published: (2011-09-01)

Psoriatic arthritis: treatment strategies using anti-inflammatory drugs and classical DMARDs
by: E. Lubrano, et al.
Published: (2012-06-01)

Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept
by: Malaviya AP, et al.
Published: (2012-08-01)

Common Transcriptomic Effects of Abatacept and Other DMARDs on Rheumatoid Arthritis Synovial Tissue
by: Clement Triaille, et al.
Published: (2021-08-01)

Cannot write session to /tmp/vufind_sessions/sess_0br62rn8h40takpi0c8vm599i7